1.Cocconi G, Gunningham D, Van Custem E. et al. Open,randomized,multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with colorectal cancer.Tomudex Colorectal Cancer Group. J. Clin. Oncol. 1998 ;16: 2943-2952.
2 Avallone A, Delrio P, Guida C et al., Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. Br J Cancer. 2006 Jun 19; 94(12):1809-15. Epub 2006 May 30.
3. Gebbia V, Verderame F. et al. Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. Ann Oncol. 2006 Jun;17 Suppl 7:vii60-vii65.
4 Feliu J, Casta et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer. 2005 Nov 28;93(11):1230-5.
5 Vyzula R, Dusek L, et al. Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Neoplasma. 2006;53(2):119-27.
6. Maroun JA, Jonker D, Seymour L et al. A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. Eur J Cancer. 2006 Jan;42(2):193-9. Epub 2005 Dec 5.
7. Au, J. L., and Sadee, W. The pharmacology of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil). Recent Res. Cancer Res. 76:100-114, 1981.
8. Au, J. L., Wu, A. T., Friedman, M. A., and Sadee, W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat. Rep., 63:343-350, 1979
9. Anttila MI, Sotaniemi EA, Kairaluoma MI, et all. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol (1983) 10: 150-153